An FDA Win For AstraZeneca Shifts To An Expanded Label In The Type 2 Diabetes Market
(WorldNews Health)

AstraZeneca (AZN) announced that it had received approval for Qternmet XR as an oral adjunct treatment to diet and exercise for glycemic control in adults with type 2 diabetes (T2D). This is good news for the company because it has already received approval for a doublet therapy for the very same patient population. In addition, AstraZeneca recently reported strong sales from several of its products in the first quarter earnings report. The higher than expected earnings were driven by sales from the Oncology business, especially the company`s top selling cancer drug Tagrisso. FDA Approval Opens Up New Option for Diabetics The FDA approval for Qternmet XR is a good approval because it comes...